FTC Derides Pay-To-Delay Deals With Generics

Drugmakers win, consumers lose. That's the message from the Federal Trade Commission, which released its latest annual report on the deals between brand-name and generic drugmakers. In fiscal year 2007, which ended September 30, 2007, there were 33 final settlements. Of those, 14, or 42 percent,... [read full story]